default author photo

Yoshimasa Takahashi

National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development

Tokyo

Japan

  • National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development

SCHOLARLY PAPERS

5

DOWNLOADS

373

TOTAL CITATIONS

2

Scholarly Papers (5)

Actions:
Email selected abstracts
1.

Optimised Lipid Nanoparticle-mRNA Vaccine Design: Minimising Pyrogenicity While Preserving Immunogenicity Through Immune Profiling

Number of pages: 63 Posted: 27 Feb 2025
Tomohiro Takano, Keigo Kumagai, Hitoshi Iuchi, Kazutaka Terahara, Aya Mizuike, Eita Sasaki, Yu Adachi, Ryutaro Kotaki, Shinichiro Ota, Mizuki Fujisawa, Tomoharu Mizukami, Kyoko Saito, Masanori Isogawa, Kohei Soga, Haruyo Nakajima-Adachi, Satoshi Hachimura, Kouji Kobiyama, Ken J. Ishii, Michiaki Hamada, Masayoshi Fukasawa, Masaharu Shinkai, Takayuki Matsumura and Yoshimasa Takahashi
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Waseda University, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Tokyo Shinagawa Hospital, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, The University of Tokyo, The University of Tokyo, The University of Tokyo, The University of Tokyo, The University of Tokyo, Waseda University, National Institute of Infectious Diseases, Tokyo Shinagawa Hospital, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 213 (357,858)

Abstract:

Loading...

mRNA vaccine, lipid nanoparticle, ionisable lipid, vaccine reactogenicity, interleukin-1

2.

Broad Neutralization Activity of SARS-CoV-2 Antibody is Achieved by Coordinated Recognition of Virus Vulnerable Site

Number of pages: 52 Posted: 01 Apr 2021
Taishi Onodera, Shunsuke Kita, Yu Adachi, Saya Moriayma, Akihiko Sato, Takao Nomura, Takeshi Inoue, Takashi Tadokoro, Yuki Anraku, Kohei Yumoto, Cong Tian, Hideo Fukuhara, Michihito Sasaki, Yasuko Orba, Nozomi Shiwa, Naoko Iwata, Noriyo Nagata, Tateki Suzuki, Jiei Sasaki, Tsuyoshi Sekizuka, Keisuke Tonouchi, Shuetsu Fukushi, Hiroyuki Satofuka, Yasuhiro Kazuki, Lin Sun, Mitsuo Oshimura, Tomohiro Kurosaki, Makoto Kuroda, Tadaki Suzuki, Hirofumi Sawa, Takao Hashiguchi, Katsumi Maenaka and Yoshimasa Takahashi
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Hokkaido University - Laboratory of Biomolecular Science, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Hokkaido University - Division of Molecular Pathobiology, Hokkaido University - Center for Research and Education on Drug Discovery, Osaka University - Laboratory of Lymphocyte Differentiation, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Laboratory of Biomolecular Science, Hokkaido University - Division of Molecular Pathobiology, Hokkaido University - Division of Molecular Pathobiology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, Kyushu University - Department of Virology, Kyushu University - Department of Virology, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Department of Virology I, Tottori University - Chromosome Engineering Research Center, Tottori University - Chromosome Engineering Research Center, National Institute of Infectious Diseases - Department of Immunology, Trans Chromosomics Inc., Osaka University - Laboratory of Lymphocyte Differentiation, National Institute of Infectious Diseases - Pathogen Genomic Center, National Institute of Infectious Diseases - Department of Pathology, Hokkaido University - Division of Molecular Pathobiology, Kyushu University - Department of Virology, Hokkaido University - Laboratory of Biomolecular Science and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 49 (1,074,648)

Abstract:

Loading...

3.

Reduced Resistance of SARS-CoV-2 Variants Toward Affinity-Matured Serological Immunity

Number of pages: 58 Posted: 21 Apr 2021
Saya Moriayma, Yu Adachi, Takashi Sato, Keisuke Tonouchi, Lin Sun, Shuetsu Fukushi, Souichi Yamada, Hitomi Kinoshita, Kiyoko Nojima, Takayuki Kanno, Minoru Tobiume, Keita Ishijima, Yudai Kuroda, Park Eunsil, Taishi Onodera, Takayuki Matsumura, Tomohiro Takano, Kazutaka Terahara, Masanori Isogawa, Ayae Nishiyama, Ai Kawana-Tachikawa, Masaharu Shinkai, Natsuo Tachikawa, Shigeki Nakamura, Takahiro Okai, Kazu Okuma, Tetsuro Matano, Tsuguto Fujimoto, Ken Maeda, Makoto Ohnishi, Takaji Wakita, Tadaki Suzuki and Yoshimasa Takahashi
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Department of Immunology, National Institute of Infectious Diseases - Department of Virology I, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - AIDS Research Center, Tokyo Shinagawa Hospital, Yokohama Municipal Citizen's Hospital - Division of Infectious Disease, Tokyo Medical University, affiliation not provided to SSRN, National Institute of Infectious Diseases, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Department of Bacteriology I, National Institute of Infectious Diseases - Department of Virology II, National Institute of Infectious Diseases - Department of Pathology and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 43 (1,145,425)

Abstract:

Loading...

4.

Neutralizing Antibody-Independent SARS-CoV-2 Control Correlated with Intranasal Vaccine-Induced CD8 + T-Cell Responses

Number of pages: 40 Posted: 15 Sep 2021
Hiroshi Ishii, Takushi Nomura, Hiroyuki Yamamoto, Masako Nishizawa, Trang Thi Thu Hau, Shigeyoshi Harada, Sayuri Seki, Midori Nakamura-Hoshi, Midori Okazaki, Sachie Daigen, Ai Kawana-Tachikawa, Noriyo Nagata, Naoko Iwata-Yoshikawa, Nozomi Shiwa, Tadaki Suzuki, Park Eunsil, Ken Maeda, Taishi Onodera, Yoshimasa Takahashi, Kohji Kusano, Ryutaro Shimazaki, Yuriko Suzaki, Yasushi Ami and Tetsuro Matano
National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - AIDS Research Center, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Pathology, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Department of Veterinary Science, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, ID Pharma Co., Ltd., ID Pharma Co., Ltd., National Institute of Infectious Diseases - Management Department of Biosafety and Laboratory Animal, National Institute of Infectious Diseases - Management Department of Biosafety and Laboratory Animal and National Institute of Infectious Diseases - AIDS Research Center
Downloads 36 (1,236,159)
Citation 1

Abstract:

Loading...

COVID-19, vaccine, CD8+ T cell, viral vector, variant

5.

Distinct Immune Cell Dynamics Correlate with the Immunogenicity and Reactogenicity of SARS-CoV-2 mRNA Vaccine

Number of pages: 71 Posted: 04 Nov 2021
Tomohiro Takano, Miwa Morikawa, Yu Adachi, Kiyomi Kabasawa, Nicolas Sax, Saya Moriayma, Lin Sun, Masanori Isogawa, Ayae Nishiyama, Taishi Onodera, Kazutaka Terahara, Keisuke Tonouchi, Masashi Nishimura, Kentaro Tomii, Kazuo Yamashita, Takayuki Matsumura, Masaharu Shinkai and Yoshimasa Takahashi
National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital, KOTAI Biotechnologies, Inc., National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital, National Institute of Advanced Industrial Science and Technology (AIST) - Artificial Intelligence Research Center (AIRC), KOTAI Biotechnologies, Inc., National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development, Tokyo Shinagawa Hospital and National Institute of Infectious Diseases - Research Center for Drug and Vaccine Development
Downloads 32 (1,290,922)
Citation 1

Abstract:

Loading...

SARS-CoV-2, Vaccine, Reactogenicity, immune correlates